Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Krystal Biotech, Inc. (KRYS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/07/2023 8-K Quarterly results
Docs: "Krystal Biotech Announces Second Quarter 2023 Financial Results and Operational Highlights"
07/26/2023 8-K Quarterly results
05/23/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/19/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEKTM for the Treatment of Dystrophic Epidermolysis Bullosa",
"Updated Risk Factors"
05/11/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PA BACKGROUND STUDY DESIGN AND METHODS RESULTS DISCUSSION CONCLUSION ACKNOWLEDGEMENTS"
05/08/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sales Agreement, by and between Krystal Biotech, Inc. and Cowen and Company, LLC",
"Opinion of Morrison & Foerster LLP"
05/08/2023 8-K Quarterly results
Docs: "Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights"
04/24/2023 8-K Quarterly results
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Krystal Biotech Appoints Catherine Mazzacco to Board of Directors"
02/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress"
01/09/2023 8-K Quarterly results
11/17/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/18/2022 8-K Quarterly results
08/08/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/23/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Slide Presentation for Investor Conference Call"
03/22/2022 8-K Investor presentation
Docs: "Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for KB301, an Investigational Gene-based Treatment Designed to Address the Underlying Biology of Aging Skin",
"A GENE-BASED AESTHETICS COMPANY March 2022 1 Exhibit 99.2 Forward Looking Statement 2 This"
03/15/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Krystal Biotech Announces Settlement with PeriphaGen, Inc."
02/28/2022 8-K Quarterly results
01/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors"
12/03/2021 8-K Quarterly results
11/29/2021 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK ™ in Patients with Dystrophic Epidermolysis Bullosa",
"Investor Slide Presentation"
11/08/2021 8-K Quarterly results
Docs: "Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress"
09/16/2021 8-K Quarterly results
08/19/2021 8-K/A Quarterly results
08/09/2021 8-K Quarterly results
08/02/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Jeune Aesthetics Announces Initiation of Dosing in Efficacy Cohort of KB301 Phase 1 trial to Assess Improvement in Skin Quality"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy